

**OPEN ACCESS**

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Frontiers Editorial Office
✉ research.integrity@frontiersin.org

RECEIVED 27 February 2024
ACCEPTED 27 February 2024
PUBLISHED 04 March 2024

CITATION
Frontiers Editorial Office (2024) Retraction:
CSF p-tau as a potential cognition impairment
biomarker in ALS. *Front. Neurol.* 15:1392563.
doi: 10.3389/fneur.2024.1392563

COPYRIGHT
© 2024 Frontiers Editorial Office. This is an
open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.

Retraction: CSF p-tau as a potential cognition impairment biomarker in ALS

Frontiers Editorial Office*

A Retraction of the Original Research Article

[CSF p-tau as a potential cognition impairment biomarker in ALS](#)

by Gong, Z., Gao, L., Lu, Y., and Wang, Z. (2022). *Front. Neurol.* 13:991143.
doi: 10.3389/fneur.2022.991143

The journal retracts the 01 November 2022 article cited above.

Following publication, concerns were raised regarding the validity of the data in the article. The authors failed to provide the raw data during the investigation, which was conducted in accordance with Frontiers' policies. Given the lack of raw data, the editors no longer have confidence in the findings presented. The article is therefore retracted.

This retraction was approved by the Chief Editors of Frontiers in Neurology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.

Frontiers would like to thank the concerned reader who contacted us regarding the published article.